Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251057 | 0.89 | STS (0.32) | STS | |
| SCHEMBL4589557 | 0.89 | STS (0.32) | STS | |
| SCHEMBL4589127 | 0.85 | NR3C1 (0.37) | STS | |
| SCHEMBL6250785 | 0.74 | NR3C1 (0.38) | STS | |
| SCHEMBL4590230 | 0.74 | NR3C1 (0.38) | STS | |
| SCHEMBL6232522 | 0.71 | NR3C1 (0.41) | STS | |
| SCHEMBL6232518 | 0.71 | NR3C1 (0.41) | STS | |
| SCHEMBL4589553 | 0.70 | — | — | |
| SCHEMBL4589116 | 0.68 | MAPK1 (0.41) | STS | |
| SCHEMBL3848400 | 0.66 | STS (0.31) | STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | claimed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | claimed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | claimed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | claimed |
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | STS 430/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | STS 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.